Artificial intelligence and precision medicine: a pilot study predicting optimal ceftaroline dosage for pediatric patients.

Background: Accurate drug dosing in pediatrics is complicated by age-related physiological variability. Standard weight-based dosing may result in either subtherapeutic exposure or toxicity. Machine learning (ML) models can capture complex relationships among clinical variables and support individualized therapy. Methods: We analyzed clinical and pharmacokinetic data from 20 pediatric patients enrolled in the PUERI study (January 2020-November 2021, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy). Eight ML models-including linear regression (LR), ridge regression (RR), lasso regression (LaR), Huber regression (HR), random forest (RF), XGBoost, LightGBM, and a neural network (MLP)-were trained to predict ceftaroline doses that would achieve plasma concentrations close to the therapeutic target of 10 mg/L. Model performance was evaluated using mean absolute error (MAE), root mean squared error (RMSE), and the coefficient of determination (R Results: MLP (MAE 1.53 mg, R Conclusion: Advanced ML models can optimize ceftaroline dosing in pediatric patients and outperform traditional dosing strategies. Combining predictive accuracy with interpretability (via LIME) supports clinical trust and may enhance precision antibiotic therapy while reducing the risks of antimicrobial resistance and toxicity.